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currence of the lesion.  Conclusion: Ingenol mebutate can-
not be considered a standard treatment modality for all 
types of LM. Further studies are needed to evaluate the pre-
requisites that can ensure therapeutic success. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Lentigo maligna (LM) is a melanoma in situ of chron-
ically sun-exposed skin, particularly, of the head and 
neck area  [1] . It develops mainly in elderly patients. 
When untreated, LM is associated with a 5–50% risk of 
progressing to invasive LM melanoma, but the exact de-
terminants for this transformation are still to be eluci-
dated  [2, 3] . Many therapeutic modalities, including sur-
gery, cryotherapy, radiotherapy and imiquimod cream, 
have demonstrated an efficacy in the treatment of LM 
 [4] . Surgical excision employing safety margins (usually 
micrographically controlled) remains the first-line ther-
apy for this pathology. Recently, a new topical treatment 
with ingenol mebutate (0.015% gel) has been described 
to be efficacious and well tolerated in the treatment of 
melanoma in situ  [5] .
 We present a case of a patient with LM on the face who 
was treated with ingenol mebutate, but relapsed 3 months 
after treatment.
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 Abstract 
 Background: Lentigo maligna (LM) is a melanoma in situ on 
sun-damaged skin, with a strong predilection to the head 
and neck area of the elderly. Many therapeutic modalities 
have been proposed in the treatment of this pathology, in-
cluding surgery, cryotherapy, radiotherapy and topical im-
iquimod. Up to date surgical excision remains the treatment 
of choice with the lowest recurrence rate. Recently, a new 
topical treatment with ingenol mebutate has been described 
to be efficacious and well tolerated in the treatment of mel-
anoma in situ.  Objective: We sought to demonstrate that 
ingenol mebutate might be an efficacious and well-tolerat-
ed treatment in a patient suffering from LM on an aestheti-
cally challenging location.  Methods: Case report.  Results: 
After therapeutic failure with imiquimod 5% cream, a new 
topical treatment with ingenol mebutate gel 0.015% once 
daily on 3 consecutive days was initiated. Despite visible in-
flammation, no macroscopic lesion clearance was observed. 
While the first follow-up using reflectance confocal micros-
copy (RCM) performed at 6 weeks after the completion of the 
therapy showed no signs of LM, the second follow-up ex-
amination at 12 weeks using RCM and biopsy confirmed re-
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 Case Report 
 A 70-year-old Caucasian woman, with a history of a multifocal 
hepatocellular carcinoma with pulmonary and lymph node metas-
tases, presented to our outpatient clinic with a pigmented and slow-
ly, but gradually enlarging macule on the face. The physical exam-
ination including dermoscopy showed a poorly demarcated light to 
dark brown macule measuring 2 × 1 cm with black dots and asym-
metric pigmented follicular openings on her left cheekbone. The 
lesion was further examined by reflectance confocal microscopy 
(RCM; Vivascope 1500, Mavig AG, Germany) revealing a disturbed 
architecture of the epidermis with a presence of numerous, large, 
round and dendritic pleomorphic cells, distributed in all epidermal 
layers, suggesting pagetoid spread of atypical melanocytes. An in-
creased proliferation of atypical melanocytes was observed espe-
cially along adnexal structures. In the dermis, non-edged papillae 
and solar damage were the commonest findings ( fig. 1 ). Histologi-
cal examination of the 4-mm punch biopsy specimen taken in the 
area guided by RCM confirmed the diagnosis of LM ( fig. 1 ).
 Informed consent for image acquisition, biopsy specimen sam-
pling and treatment (including evidence-based and off-label use) 
was obtained from the patient. On account of her age and comor-
bidities, as well as the cosmetically challenging localization and 
size of the lesion, the patient declined a surgery.
 Therefore, an alternative treatment with imiquimod cream 5% 
was initiated. The patient was instructed to apply the cream, cover-
ing the affected area and a 1-cm margin of the surrounding skin 
twice daily 7 days a week. After 8 weeks of treatment, no inflam-
matory reaction was observed. Hence, the topical treatment was 
changed to ingenol mebutate gel 0.015%. Three consecutive daily 
applications of the gel were performed on the lesion and 1 cm of 
the adjacent skin once daily for 3 days. At the end of the 3-day 
treatment a strong inflammatory, crusting and oozing reaction on 
the application site developed ( fig. 2 ).
 In the follow-up RCM examination, at 6 weeks after comple-
tion of the treatment, no criteria for LM were found. Clinically 
and dermoscopically, a lentiginous pigmented macule was still 
visible on the face ( fig. 3 ). The follow-up examination with RCM 
performed after 12 weeks of treatment with ingenol mebutate 
showed a relapse of the LM. A 4-mm punch biopsy confirmed LM 
( fig. 4 ).
 Discussion 
 Ingenol mebutate is a hydrophobic diterpene ester 
isolated from a sap of a plant  Euphorbia peplus , com-
monly known as a ‘petty spurge’ in the United Kingdom 
or ‘radium weed’ in Australia, that has a long tradition 
of use for a variety of conditions, including skin cancer 
 [6] . Ingenol mebutate has been registered in the USA 
a
b c d
 Fig. 1. Clinical ( a ), dermoscopic ( b ), confocal ( c ) and histological ( d ) picture of LM at baseline. 
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 Fig. 3. Clinical ( a ), dermoscopic ( b ) and confocal picture ( c ) of LM at 6 weeks after the treatment with ingenol 
mebutate. 
 Fig. 2. Strong local inflammatory response 
after the treatment with ingenol mebutate. 
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and Europa as a local treatment for actinic keratosis  [7–
10] . In addition to its approved use, ingenol mebutate 
has emerged in the last years as an efficient topical agent 
for the treatment of Bowen’s disease  [11] , superficial bas-
al cell carcinoma  [12] and molluscum contagiosum  [13] .
 To date, there is only one report on successful treat-
ment of recurrent melanoma in situ with ingenol mebu-
tate (0.015% for 3 days) at 6 months of follow-up  [5] .
 Ingenol mebutate has been demonstrated to induce 
both non-apoptotic and apoptotic cell death in several 
malignant cell lines, including melanoma. Analysis of 
murine melanoma cells in vivo and in vitro with an elec-
tron microscopy confirmed a relatively rapid necrotic cell 
death after disintegration of the plasma membrane and 
disruption of cytoplasmic organelles with a loss of mito-
chondrial potential, following an exposure to topical in-
genol mebutate  [14] . The same study demonstrated a ne-
crosis of other tumor cell lines (including human prostate 
carcinoma, breast adenocarcinoma and acute leukemia) 
confirming cytotoxic cell death and consequently low 
specificity of the drug at the concentrations used for dif-
ferent tumor cell types. Development of a rapid, strong, 
cytotoxic reaction as described above was also observed 
in our case.
 Apart from its cytotoxic properties, ingenol mebutate 
is a protein kinase C activator  [15] and induces apoptosis 
in caspase-dependent way  [16] . In an in vitro study on 
different melanoma cell lines, ingenol mebutate induced 
cell death in all of the cultured melanoma cell lines. How-
ever, only in 20% of human melanoma cell lines was cell 
death a result of apoptosis, the rest resulting from necro-
sis. The exact mechanism of melanoma cell lines sensitiv-
ity to apoptosis after treatment with ingenol mebutate has 
not been completely elucidated.
 Cozzi et al.  [17] observed that treatment with ingenol 
mebutate caused a selective and irreversible induction of 
cell senescence in only certain sensitive melanoma cell 
lines.  BRAF genotypes of the melanoma cell lines used in 
the study showed no correlation with the treatment out-
come, with all sensitive cell lines mutated at either  NRAS 
or  BRAF loci. The authors hypothesize that the induction 
of senescence in some of the melanoma cell lines might 
have been achieved by activation of MAPK pathway. 
Moreover, the tumor suppressor gene  HRASL3/
 Fig. 4. Clinical ( a ), dermoscopic ( b ), confocal ( c ) and histological ( d ) picture of a recurrent LM at 12 weeks after 
the treatment with ingenol mebutate. 
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HREV107 was higher expressed in melanoma cell lines 
resistant to ingenol mebutate treatment. Hence, they 
speculate that certain criteria must be present to render 
melanoma cells susceptible to senescence, namely, the 
presence of an activating  NRAS or  BRAF mutation and 
low transcriptional levels of the MAPK inhibitor 
 HREV107 .
 In our patient, treatment of LM with ingenol mebutate 
led to a transient clearance of melanoma cells, confirmed 
by RCM examination, but did not result in remission of 
the lesion.
 The described therapeutic effect of ingenol mebutate 
is superficial and is therefore expected to act mainly in 
superficial tumors. In case of a LM, proliferating mela-
nocytes may penetrate deep into the skin, along the ad-
nexal structures. Hence, the reduced absorption/pene-
tration of the drug might explain the therapeutic failure. 
RCM is a non-invasive imaging technique that enables 
in vivo visualization of the epidermis down to the papil-
lary dermis in real time. Resolution is almost compara-
ble to conventional histology. Therefore, incompletely 
eliminated melanoma cells from the lower levels of the 
hair follicle’s isthmus might have been undetectable on 
examination. Rapid recurrence of the lesion suggests the 
persistence of melanoma cells. Moreover, based on the 
above-mentioned in vitro studies, we can hypothesize 
that the therapeutic failure might have been caused also 
by a genetically resistant type of melanoma cells or by 
insufficient dose of the drug needed for a complete 
clearance. Furthermore, the metastasizing hepatocellu-
lar carcinoma may also have hampered the immune re-
action against the melanoma cells. Further studies, es-
pecially in vivo and on larger series of subjects are need-
ed to better evaluate the efficacy of the treatment with 
ingenol mebutate in melanocytic tumors.
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